How Should My Prostate Cancer Be Treated?

Every patient and cancer is unique, so here at Sarasota Prostate Care, we individually tailor each patient’s treatment plan. The best prostate cancer treatment for your particular cancer is likely different than the treatment your father, neighbor or friend had. Your treatment choice will be based on both cancer factors and patient factors.

What Is My Prostate Cancer Risk?
Low Risk = Gleason ≤ 6, PSA 10 Or Less, Clinical Stage T2B or Less
Intermediate Risk = Gleason 7, PSA 10-20, Clinical Stage T2C
High Risk = Gleason 8-10, PSA > 20, Clinical Stage T3 or Greater

Cancer Factors

Treatment selection depends on a variety of clinical factors, including the cancer stage, Gleason score and tumor volume. This information helps determine if your cancer is “clinically significant,” which requires definitive treatment. Prostate cancer is considered “clinically significant” if it would cause significant morbidity and/or mortality if left untreated. This is critical distinction, since cancers that are “clinically insignificant” do not necessarily need to be actively treated. Those are the cancers that men “die with,” not “die from.”

We sometimes need to obtain a CT and/or bone scan for patients with intermediate risk or high-risk disease to rule out any evidence of metastatic disease.

There are additional tests that can be performed to help further characterize your cancer. These include the Oncotype DX GPS Score and the Prolaris Test. These are genetic tests of your pathology slides that evaluate your cancer’s aggressive potential. Sarasota Prostate Care is proud to be one of the few prostate cancer treatment centers to offer these studies to all patients.

Personal Factors

Your age, general health, life expectancy, personal preferences and your willingness or ability to tolerate the potential side effects of treatment are all key factors in choosing the best treatment option.

Pre-existing sexual function and urinary symptoms are also very important, since these can potentially be affected to varying degrees by most prostate cancer treatments.